HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Healthcare
Avelios Medical
Series A in 2025
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Akribion Genomics
Seed Round in 2025
Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.
Laclarée
Seed Round in 2025
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.
Refoxy Pharma
Seed Round in 2024
Refoxy Pharma develops therapeutic medicines intended to treat age-related diseases and promote healthy longevity. It researches proteins that regulate multiple genes involved in stress resistance and metabolism and develops novel modulators of a central stress response pathway to influence aging through genetics, with the aim of extending the years of healthy living for patients.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology company specializing in the development of minimally invasive devices for obesity treatment. Their flagship product is a cryo catheter that, in a single, brief procedure akin to a gastroscopy, freezes and ablates the gastric branches of the vagus nerve, reducing hunger and promoting weight loss. This outpatient procedure offers a less invasive alternative to traditional obesity treatments.
SRTD Biotech
Seed Round in 2024
SRTD Biotech is a biotechnology company specializing in RNA-based therapies. It develops a pro-drug platform targeting various diseases, including cancer, viral infections, and genetic disorders. The company's approach involves selectively delivering RNAs to patients using techniques such as RNAi interference, mRNA, and fusogenic liposomes for organ-specific targeting, aiming to treat previously incurable conditions.
Mediaire
Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
BIOVOX
Seed Round in 2024
BIOVOX develops sustainable plastic materials tailored for healthcare applications. Their compounds are renewable, degradable, recyclable, and offer rigidity, surface hardness, and transparency, enabling medical manufacturers to reduce environmental impact while maintaining high safety standards.
All3DP
Venture Round in 2024
Founded in Munich, Germany in 2014, All3DP is a leading online platform dedicated to 3D printing. It publishes a magazine offering guidance and practical information for both beginners and professionals, covering various industries such as aerospace, automotive, healthcare, and more. The platform also hosts Craftcloud, a global marketplace that compares prices from top manufacturers in real-time.
Symphera
Seed Round in 2024
Symphera is a developer of an innovative surgical system focused on enhancing the efficiency of minimally invasive procedures. The company specializes in a laparoscopic surgical tool that aims to radically simplify and expedite surgical processes. By prioritizing control, autonomy, safety, and efficiency, Symphera enables healthcare providers to perform surgeries with greater precision and effectiveness. Through its all-in-one surgical system, the company is committed to transforming the landscape of surgical practices, making advanced medical techniques more accessible and streamlined for both practitioners and patients.
HepaRegenix
Series C in 2024
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
SciRhom
Series A in 2024
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
CustomSurg
Seed Round in 2024
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Altavo
Series A in 2024
Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.
RAYDIAX
Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.
Inovedis
Series A in 2023
Inovedis specializes in innovative medical technologies aimed at optimizing patient care while reducing time and costs within the healthcare sector. The company develops advanced surgical devices, such as its flagship product designed for treating shoulder injuries, which leverages science-based technology to enable anatomical reconstruction of physiological tendon-bone connections.
Kranus Health
Series A in 2023
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
InContAlert
Pre Seed Round in 2023
InContAlert is a deep tech company innovating in the field of incontinence management. It develops an mHealth device that monitors urinary bladder filling levels using advanced algorithms. The device sends alerts to users and caregivers when predefined thresholds are reached, minimizing risks associated with uncontrolled urine loss or bladder distension.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
smartbax
Seed Round in 2023
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Dualyx
Series A in 2023
Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.
Nia Health
Seed Round in 2023
Nia Health develops digital health applications focused on dermatological conditions like eczema and psoriasis. Its AI-powered app provides personalized support and relief, aiming to improve patient outcomes through innovative digital solutions.
DearEmployee
Seed Round in 2023
DearEmployee GmbH is a Berlin-based company that specializes in a software-as-a-service application focused on workplace mental health. Founded in 2017, it provides a platform designed to help employers assess and manage mental stress in their organizations. The platform allows companies to scientifically measure psychological stress levels among employees and implement tailored health and HR initiatives. By addressing mental health concerns, DearEmployee aims to foster healthier and more motivating working conditions, ultimately enhancing employee productivity. Additionally, the solution complies with legal requirements for mental health risk assessments in Germany, positioning it as a vital resource for organizations committed to employee well-being.
Phialogics
Pre Seed Round in 2023
Phialogics is a biotechnology company focused on developing innovative biologics to regulate the immune response in both acute and chronic inflammation. Its platform enables the creation of engineered antibodies and cell-type-specific immune checkpoint activators, targeting autoimmune diseases such as lupus, type 1 diabetes, and rheumatoid arthritis.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.
Selfapy
Venture Round in 2023
Selfapy develops an online therapy platform focused on treating depression and associated mental health issues. It offers guided, anonymous, and flexible programs, including exercises, videos, and texts, delivered via phone or SMS over three months.
PraxisEins.
Pre Seed Round in 2023
PraxisEins is a healthcare startup focused on enhancing outpatient care through innovative technology. The company develops a software-enabled platform that assists physicians in digitizing their processes, ultimately aimed at improving patient care and alleviating administrative burdens. By leveraging modern technology, PraxisEins enables doctors to conduct same-day consultations with patients, addressing the supply vacuum in outpatient services. Through its solutions, the company seeks to streamline workflows for healthcare providers and enhance the overall efficiency of outpatient care.
neotiv
Seed Round in 2022
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
Resolve BioSciences
Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
Kupando
Series A in 2022
Kupando is a biopharmaceutical company focused on developing immunostimulatory agents targeting toll-like receptors. Its mission is to create affordable immunotherapy options for cancer patients and prevent infectious diseases.
FaCellitate
Seed Round in 2022
FaCellitate is a developer of innovative biomedical technology focused on enhancing cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The company specializes in creating polymeric platforms that provide chemically defined, animal- and xeno-free cell culture coatings. These advanced coatings facilitate improved cellular interactions, thereby significantly enhancing cell culture practices in biological research. By offering smart lab surfaces, FaCellitate enables researchers to conduct more effective experiments, contributing to advancements in various fields of biomedical research.
C-mo Medical Solutions
Seed Round in 2022
C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.
Kranus Health
Series A in 2022
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Invasight
Seed Round in 2022
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Ebenbuild
Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.
Altavo
Seed Round in 2022
Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Nebula Biocides
Seed Round in 2021
Nebula Biocides is a company that specializes in the development of innovative disinfection solutions aimed at effectively combating infection. The company focuses on creating application-oriented products that target persistent bacterial spores and resilient viruses, ensuring comprehensive protection for users in various environments. Nebula Biocides offers a range of smart disinfection devices designed to deliver reliable and efficient disinfection, making them suitable for diverse applications. Through its commitment to effective infection control, Nebula Biocides strives to enhance public health and safety by providing advanced disinfection technologies.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Alentis Therapeutics
Series B in 2021
Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.
ReActive Robotics
Venture Round in 2021
Founded in 2015, ReActive Robotics designs, manufactures, and sells rehabilitation robots for early movement rehabilitation post neurological injury or orthopedic surgery. Its robots aid in gait rehabilitation for neurological patients and joint replacement recovery.
ActiTrexx
Series A in 2021
ActiTrexx is a biotechnology company developing cellular therapies to mitigate inflammatory reactions in conditions such as graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune disorders. Their flagship product, ATREGA, aims to enhance survival rates for transplanted patients.
GeneQuine Biotherapeutics
Series A in 2021
Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.
Kranus Health
Seed Round in 2021
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Mediaire
Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Resolve BioSciences
Series A in 2020
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
Synendos Therapeutics
Series A in 2020
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.
All3DP
Series A in 2020
Founded in Munich, Germany in 2014, All3DP is a leading online platform dedicated to 3D printing. It publishes a magazine offering guidance and practical information for both beginners and professionals, covering various industries such as aerospace, automotive, healthcare, and more. The platform also hosts Craftcloud, a global marketplace that compares prices from top manufacturers in real-time.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Atriva Therapeutics
Debt Financing in 2020
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
NovaPump
Series A in 2020
NovaPump specializes in developing non-invasive and percutaneous heart assist devices. Its flagship product is PERKAT, a self-expanding heart pump designed for acute left or right heart patients. PERKAT complements existing intra-aortic balloon pumps and offers advantages such as high pump performance, cost-effectiveness, and ECG triggering.
iATROS
Seed Round in 2020
iATROS GmbH is a Munich-based company founded in 2019 that specializes in developing a mobile application and platform aimed at enhancing the care of cardiology patients. The platform connects patients with medical caregivers and offers a range of services, including therapy and medication planning, progress tracking, ECG diagnosis, and the maintenance of blood pressure and sugar databases. It also facilitates consultations with physicians and enables the secure storage of health data. As the prevalence of cardiovascular diseases increases, iATROS aims to improve the lives of both chronic and acute patients while addressing the significant healthcare costs associated with these conditions. By leveraging smart health trackers, vital data collection, and advanced AI analytics, the company enhances treatment outcomes and provides patients with 24/7 access to healthcare professionals, ensuring they feel safe in managing their conditions.
Scipio Bioscience
Series A in 2020
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
Selfapy
Series A in 2020
Selfapy develops an online therapy platform focused on treating depression and associated mental health issues. It offers guided, anonymous, and flexible programs, including exercises, videos, and texts, delivered via phone or SMS over three months.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
Biograil
Seed Round in 2020
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is a medical device company focused on developing innovative delivery systems for biologic substances. The company has designed a device that is encapsulated in a standard-sized capsule, utilizing injection molding technology. This device eliminates mechanical moving components and harnesses the body's natural peristaltic forces to facilitate the effective and painless delivery of medications directly into the gastrointestinal wall. By replacing traditional injection methods, Biograil aims to enhance patient comfort and improve the administration of medications.
Mecuris
Series B in 2020
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
DearEmployee
Venture Round in 2019
DearEmployee GmbH is a Berlin-based company that specializes in a software-as-a-service application focused on workplace mental health. Founded in 2017, it provides a platform designed to help employers assess and manage mental stress in their organizations. The platform allows companies to scientifically measure psychological stress levels among employees and implement tailored health and HR initiatives. By addressing mental health concerns, DearEmployee aims to foster healthier and more motivating working conditions, ultimately enhancing employee productivity. Additionally, the solution complies with legal requirements for mental health risk assessments in Germany, positioning it as a vital resource for organizations committed to employee well-being.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Laclarée
Seed Round in 2019
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.
Draupnir Bio
Seed Round in 2019
Draupnir Bio is a biotechnology company focused on developing a new class of cholesterol-lowering medicines to prevent heart blood clots more effectively than existing therapies. The company pursues a platform that maps and leverages the glycome to build heparan sulfate glycomimetics, enabling synthesis, screening, and selection of potent, specific drug candidates for cardiovascular, inflammatory, and infectious diseases. Leveraging its technology, the firm aims to develop protein degraders that target extracellular disease proteins, potentially broadening therapeutic reach across unmet medical needs. The approach seeks to offer convenient treatment options that could reduce reliance on traditional injectables. Through its glycome-based platform, Draupnir Bio targets modalities beyond small molecules, with a focus on extracellular targets and biologics-compatible strategies to improve patient outcomes.
Vacis
Venture Round in 2019
Vacis specializes in tissue engineering technology for creating body-own blood vessels. Its platform induces the body to form functional blood vessels, offering novel therapeutic options and reducing complications associated with prosthetic vascular grafts.
Zahnarzt-Helden
Seed Round in 2019
Zahnarzt-Helden GmbH is a Bielefeld-based company that operates an online platform designed to assist dentists in identifying and acquiring essential dental equipment and services. Established in 2017, the company offers a diverse range of products, including Orthopantomograms, deep vein thrombosis scanners, Cephalometric devices, intraoral X-rays, intraoral scanners, autoclaves, thermodisinfectors, CAD/CAM systems, and management software. In addition to providing access to these products, Zahnarzt-Helden offers consultation services to help practitioners select the appropriate equipment, negotiate with manufacturers and dealers, and ensure reliable construction, maintenance, and long-term technical support. The platform aims to provide a transparent and user-friendly experience, akin to popular service comparators, allowing dental professionals to obtain favorable offers without hidden costs.
Pantherna Therapeutics
Seed Round in 2019
Pantherna Therapeutics GmbH is a biopharmaceutical company based in Hennigsdorf, Germany, founded in 2017. The company specializes in developing innovative mRNA therapeutics aimed at treating acute respiratory distress syndrome (ARDS) and vascular diseases. Pantherna Therapeutics utilizes a unique technology platform based on advanced nanoparticles that facilitate the delivery and expression of therapeutic mRNA drugs specifically in the endothelium. This approach aims to prevent the formation of edema and lung tissue injury associated with ARDS while also enabling the restoration of endothelial cell function.
miRdetect
Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.
Alentis Therapeutics
Series A in 2019
Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Mediaire
Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Cytena
Series A in 2019
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
8sense
Seed Round in 2019
8sense develops a smart back sensor and coaching system for office use that combines wearable sensors to analyze posture and movement with real-time feedback and training. Through games and challenges, it motivates users to care for their backs, and the accompanying coaching platform provides science-based recommendations to promote an active, dynamic sitting posture for better back health.
Eyeware
Seed Round in 2019
Founded in 2016, Eyeware develops software-only head and eye tracking solutions for webcams and 3D cameras. Its patent-pending computer vision algorithms enable accurate, real-time gaze tracking without specialized hardware, benefiting applications such as gaming, research, accessibility, automotive, and healthcare.
Mecuris
Series A in 2019
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Atriva Therapeutics
Series A in 2019
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
denovoMATRIX
Seed Round in 2018
Founded in 2018, denovoMATRIX develops biomimetic coatings for stem cell culture. Its products include screenMATRIX, which enhances cell adhesion and differentiation, and myMATRIX, a custom-coated tissue cultureware for serum-free media. These are used in stem cell research, tissue models, and cell-based therapies.
Amal Therapeutics
Series B in 2018
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
GWA Hygiene
Venture Round in 2018
GWA Hygiene GmbH is a German company based in Stralsund, established in 2015, that specializes in the development of hygiene monitoring solutions for healthcare settings. The company manufactures sensors designed to monitor hand hygiene standards among hospital personnel and is expanding its offerings to include surface disinfection monitoring. GWA Hygiene's technology integrates with disinfectant and soap dispensers, equipping them with sensors to capture data on disinfection practices. This data can be displayed on monitors and is accessible via a software application that analyzes disinfection rates across different wards and professional groups. Users have the option to store data on their own servers or utilize GWA Hygiene's secure cloud storage. Additionally, the company's software toolbox aids in logistical tasks related to hygiene management, such as managing dispenser refills and device maintenance.
advanceCOR
Venture Round in 2018
advanceCOR is a clinical drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Its activities span research, development, and plans for commercialization to enable personalized treatment of cardiovascular conditions. Lead candidates include Revacept, a human Fc fusion protein that prevents local platelet activation at sites of vascular injury; COR-2, a recombinant protein that interferes with foam cell formation and the uptake of cholesterol; and COR-3, a recombinant protein that binds to atherosclerotic plaques and bi-specifically captures circulating progenitor cells to promote plaque healing. The company also develops antibodies and fusion proteins targeting platelet receptors and other components involved in arterial thrombosis and plaque progression, with an emphasis on addressing acute events such as myocardial infarction and stroke.
Implandata Ophthalmic Products
Series C in 2018
Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
neotiv
Seed Round in 2018
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
5Analytics
Seed Round in 2017
Founded in 2016, 5Analytics develops an AI-based platform that automates internal IT processes for businesses. Its offerings include the 5Analytics AI Platform ADA for deploying R and Python code as web services, and Operational R software tailored for productive environments. The company serves various industries such as insurance, retail, healthcare, finance, energy, and telecommunications, providing solutions for sales management, dynamic pricing, recommendation engines, customer retention, process optimization, and predictive maintenance analysis.
RIMASYS
Venture Round in 2017
RIMASYS is dedicated to advancing surgical education and medical technology research and development. The company focuses on creating realistic fractures in human specimens through a unique algorithm and device, which supports practical skill training for surgeons. By integrating digital learning, virtual reality, and 3D printing, RIMASYS aims to improve patient outcomes and enhance the quality of life for individuals requiring advanced therapies and operations. Their innovative approach facilitates collaboration among medical science, academia, and industry, fostering the development of better implants and surgical techniques.
ReActive Robotics
Series B in 2017
Founded in 2015, ReActive Robotics designs, manufactures, and sells rehabilitation robots for early movement rehabilitation post neurological injury or orthopedic surgery. Its robots aid in gait rehabilitation for neurological patients and joint replacement recovery.
Amal Therapeutics
Series B in 2017
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
Selfapy
Seed Round in 2017
Selfapy develops an online therapy platform focused on treating depression and associated mental health issues. It offers guided, anonymous, and flexible programs, including exercises, videos, and texts, delivered via phone or SMS over three months.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.
Atriva Therapeutics
Seed Round in 2017
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, specializing in the development of drugs for neurodegenerative diseases and hearing impairments. Founded in 2010 by Professor Hans Rommelspacher, the company has assembled a team of skilled scientists and executives, supported by a network of academic partners and strategic investors. AudioCure Pharma is located in a central area of Mitte, providing access to numerous high-tech companies and universities, including close ties with the Charité University. The company is focused on advancing its leading compound, AC102, which is in late-stage preclinical development for treating acute noise-induced hearing loss and has demonstrated preclinical proof of concept since 2016.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Mecuris
Seed Round in 2016
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.